An analyst says the weight-loss drug Qsymia can't live up to investors' expectations.
Chartists, analysts and the public missed the boat on some key earnings. How else can we explain these market moves?
Stocks rise as housing starts climb more than expected.
Vivus becomes the second pharma this year approved to sell a weight-loss treatment.
If a stock is up 500% in a straight line, that's a clue.
Analysts are far from perfect. But sometimes their predictions are correct -- and can produce spectacular returns.
Stocks pare earlier gains as investors await FOMC minutes.
VIDEO ON MSN MONEY
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.
MONEY & POLITICS
Breaking up big banks is an untested solution to the too big to fail problem that attempts to isolate and dismantle large, troubled institutions while protecting the rest of the economy.
Joe Cantrell says he faces charges after trying to take advantage of the retailer's policy.
The IRS is struggling to combat identify thieves who file fraudulent tax returns in the names of older residents who don't need to file.